AMGN Amgen Inc

Price (delayed)

$233.02

Market cap

$124.65B

P/E Ratio

19.7

Dividend/share

$7.58

EPS

$11.83

Enterprise value

$155.97B

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980. ...

Highlights
The P/E is 26% below the 5-year quarterly average of 26.6 and 10% below the last 4 quarters average of 22.0
AMGN's EPS is up by 19% year-on-year and by 16% since the previous quarter
Amgen's equity has soared by 164% from the previous quarter but it has plunged by 71% YoY
The debt rose by 11% year-on-year

Key stats

What are the main financial stats of AMGN
Market
Shares outstanding
534.93M
Market cap
$124.65B
Enterprise value
$155.97B
Valuations
Price to earnings (P/E)
19.7
Price to book (P/B)
51.46
Price to sales (P/S)
4.73
EV/EBIT
17.83
EV/EBITDA
12.87
EV/Sales
5.91
Earnings
Revenue
$26.38B
EBIT
$8.75B
EBITDA
$12.12B
Free cash flow
$8.36B
Per share
EPS
$11.83
Free cash flow per share
$15.62
Book value per share
$4.53
Revenue per share
$49.32
TBVPS
$57.01
Balance sheet
Total assets
$59.29B
Total liabilities
$56.88B
Debt
$36.52B
Equity
$2.42B
Working capital
$6.7B
Liquidity
Debt to equity
15.1
Current ratio
1.53
Quick ratio
0.99
Net debt/EBITDA
2.58
Margins
EBITDA margin
45.9%
Gross margin
75.8%
Net margin
24.9%
Operating margin
35.5%
Efficiency
Return on assets
10.8%
Return on equity
144.1%
Return on invested capital
18.7%
Return on capital employed
18.7%
Return on sales
33.1%
Dividend
Dividend yield
3.25%
DPS
$7.58
Payout ratio
64.1%

AMGN stock price

How has the Amgen stock price performed over time
Intraday
1.12%
1 week
3.11%
1 month
-3.86%
1 year
10.21%
YTD
3.58%
QTD
3.38%

Financial performance

How have Amgen's revenue and profit performed over time
Revenue
$26.38B
Gross profit
$19.99B
Operating income
$9.36B
Net income
$6.58B
Gross margin
75.8%
Net margin
24.9%
AMGN's operating income is up by 26% year-on-year and by 17% since the previous quarter
The company's operating margin rose by 22% YoY and by 17% QoQ
The net income has grown by 15% from the previous quarter and by 14% YoY
The net margin rose by 15% since the previous quarter and by 11% year-on-year

Growth

What is Amgen's growth rate over time

Valuation

What is Amgen stock price valuation
P/E
19.7
P/B
51.46
P/S
4.73
EV/EBIT
17.83
EV/EBITDA
12.87
EV/Sales
5.91
The P/E is 26% below the 5-year quarterly average of 26.6 and 10% below the last 4 quarters average of 22.0
AMGN's EPS is up by 19% year-on-year and by 16% since the previous quarter
Amgen's equity has soared by 164% from the previous quarter but it has plunged by 71% YoY
The stock's price to book (P/B) is 140% more than its 5-year quarterly average of 21.4 but 12% less than its last 4 quarters average of 58.6
The P/S is 11% less than the 5-year quarterly average of 5.3 and 3.5% less than the last 4 quarters average of 4.9
The revenue has grown by 3.5% year-on-year

Efficiency

How efficient is Amgen business performance
The ROE has soared by 138% YoY and by 52% from the previous quarter
AMGN's return on assets is up by 17% year-on-year and by 16% since the previous quarter
AMGN's return on sales is up by 13% since the previous quarter and by 10% year-on-year
The ROIC has grown by 11% YoY and by 9% from the previous quarter

Dividends

What is AMGN's dividend history
DPS
$7.58
Dividend yield
3.25%
Payout ratio
64.1%
Recent dividends

Financial health

How did Amgen financials performed over time
Amgen's total assets is 4.3% more than its total liabilities
Amgen's current ratio has increased by 17% YoY and by 6% from the previous quarter
AMGN's quick ratio is up by 15% year-on-year and by 10% since the previous quarter
Amgen's equity has soared by 164% from the previous quarter but it has plunged by 71% YoY
AMGN's debt to equity has shrunk by 62% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.